Incidentally Discovered 4.5-cm Renal Mass in a Patient with CKD and Anticoagulation
A 64-year-old man is referred after a CT scan obtained for diverticulitis shows a 4.5-cm solid left renal mass. The mass enhances by 45 Hounsfield units, is exophytic and interpolar, lies about 2 cm from the renal hilum, and has no fat, calcification, venous thrombus, or metastatic deposits. His eGFR is 42 mL/min/1.73 m², and he has hypertension, a BMI of 38, and paroxysmal atrial fibrillation treated with apixaban. He is ASA class III. Hemoglobin is 11.8 g/dL and platelets 210,000/µL. He takes amlodipine and metoprolol and has no prior abdominal surgery. He has no family history of renal cancer and no flank pain or hematuria. He asks whether the mass can simply be watched because he fears dialysis. The hospital has experienced partial nephrectomy and ablation, but no robot.
1. How would you frame the trade-offs among partial nephrectomy, thermal ablation, and active surveillance for this 4.5-cm mass, and what additional information would most change your recommendation?
Read the worked answer
A 4.5-cm solid, enhancing renal mass is suspicious for renal cell carcinoma, so the starting point is oncologic control, not simply preserving renal function. Partial nephrectomy is the preferred option when technically feasible because it offers definitive pathology and durable local control while sparing nephrons; however, this patient's eGFR of 42, BMI of 38, ASA III status, and apixaban use raise perioperative risk. Thermal ablation is attractive for a small exophytic tumor, but at 4.5 cm the oncologic margin and local recurrence data are less favorable than for a 2–3-cm mass, and a biopsy is still needed. Active surveillance is reasonable if his life expectancy is limited by comorbidity or if he prioritizes avoiding intervention, but a 4.5-cm mass has meaningful growth and metastatic potential, so surveillance must be structured and revisable.
Additional information would change my recommendation: prior imaging showing growth rate; a nephrometry score and exact hilar/vascular proximity; frailty and cardiac risk; his values about dialysis versus cancer risk; and whether apixaban can be safely interrupted. I would not present surveillance as "no treatment"-it is a delayed-treatment strategy with defined triggers.
2. If partial nephrectomy is chosen, outline the perioperative plan for apixaban and the counseling you would give about renal function.
Read the worked answer
For a procedure with meaningful bleeding risk, apixaban should usually be stopped about 48 hours before surgery, with the exact interval guided by renal function and the anesthesiologist/cardiologist. Bridging is generally not required for atrial fibrillation unless he has a very high thrombotic risk such as a recent stroke or mechanical valve; avoiding unnecessary bridging also avoids a bleeding hazard. I would check a baseline creatinine and hemoglobin, avoid nephrotoxins, and resume apixaban only after surgical hemostasis is secure, typically around 24–72 hours depending on the bed and drain output.
The counseling should be explicit: partial nephrectomy is nephron-sparing but not risk-free. With baseline eGFR 42, obesity, and hypertension, he is at increased risk of acute kidney injury and long-term CKD progression even if the contralateral kidney is normal. I would discuss ischemia time, risk of urine leak or bleeding, possible conversion to radical nephrectomy, and the small but real risk of dialysis. I would involve nephrology early and document that the goal is cancer control with maximal functional preservation.
3. If he elects active surveillance, define a follow-up plan and the findings that should trigger intervention.
Read the worked answer
Active surveillance must be protocolized. I would obtain a contrast-enhanced CT or MRI at baseline and then every 3–6 months for the first 1–2 years, followed by annual imaging if growth is slow and the patient remains committed. I would document tumor size, enhancement, and nephrometry at each scan, and I would use the same modality where possible to reduce measurement error. A baseline biopsy can be discussed, but it may be nondiagnostic and carries bleeding risk on apixaban; it is not mandatory if imaging is classic and the patient understands uncertainty.
Triggers for intervention include growth greater than about 5 mm per year, diameter approaching or exceeding 4 cm, new symptoms, imaging features suggesting higher grade or local invasion, or patient preference after shared discussion. I would also intervene if follow-up cannot be guaranteed. The key is that surveillance is not a passive decision: it requires a defined schedule, a documented discussion of the risk of metastasis, and a clear pathway to partial nephrectomy or ablation if the tumor behaves aggressively.